The bioavailability of methylepoxyproscillaridin (P35): a new semisynthetic cardiac glycoside.
The pharmacokinetic data of methylepoxyproscillaridin (3'-methyl-4'-5'-epoxyproscillaridin) (P35) after 1 mg i.v. or oral administration in two different galenic preparations (hard and soft gelatin capsules) in randomized succession were studied in 9 healthy volunteers, showing a bioavailability of 88 +/- 10.5% (soft gelatin capsule) and 81 +/- 12% (hard gelatin capsule). The half-life of P35 was calculated to be 80 +/- 13.3 h.
Bonelli
J
J
St. Elisabeth Hospital Vienna, Austria.
Waginger
W
W
Gazo
F
F
D000328:Adult; D001682:Biological Availability; D002018:Bufanolides / Q000493:pharmacokinetics*; D002301:Cardiac Glycosides / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006207:Half-Life; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D011442:Proscillaridin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics*
D002018:Bufanolides; D002301:Cardiac Glycosides; C056946:methylepoxyproscillaridin; D011442:Proscillaridin